The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $208,575 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Arizona to develop and evaluate an ionic liquid-based nanoemulsion delivery system for a two-drug antiretroviral regimen containing a second-generation integrase inhibitor and non-nucleoside reverse transcriptase inhibitor. The goal is to improve the oral bioavailability and enable transdermal delivery of these combination antiretroviral drugs to provide effective long-term management of HIV infection through non-invasive means. The project will focus on formulation development, in vitro evaluation, and in vivo pharmacokinetic testing in mice to establish proof-of-concept for this approach. Successful completion of this effort is expected to yield pharmaceutically viable topical and oral nanoemulsion products containing the integrase inhibitor-NNRTI combination for HIV treatment.
Generated 3/18/25, 4:02 AM